ADA 2021 | SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes | diabetes.medicinematters.com

Register Login

Medicine Matters Diabetes

Javascript needed

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

06-28-2021 | ADA 2021 | Conference coverage | Video

SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes

Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes (3:31).

Medicine Matters Diabetes

SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes

Related content

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes

A quick guide to the SUSTAIN trials

A quick guide to the STEP trials

EASD Annual Meeting 2021 coverage

New additions to the Adis Journal Club

Medicine Matters Diabetes

SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes

External Content

Related content

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes

A quick guide to the SUSTAIN trials

A quick guide to the STEP trials

EASD Annual Meeting 2021 coverage

New additions to the Adis Journal Club